c

When Your Pain Is Finally Defined.
That’s Living Proof.

Vertebrogenic Pain Is Understood

Vertebrogenic pain is a distinct type of chronic low back pain caused by damage to vertebral endplates, the interface between the disc and the vertebral body. Disc degeneration, and the wear and tear that occurs with everyday living, produces stresses on the endplates that damage them, leading to inflammation and vertebrogenic pain.
BVN
Bending, lifting, activity, sitting

How Patients Describe Vertebrogenic Pain

The disc and endplate are both part of the anterior spinal column and produce similar low back pain symptoms. However, endplate pain is associated with distinctive changes on routine MRI called Modic changes.

Patients who find relief from the Intracept Procedure often describe pain in the middle of their low back that is made worse by physical activity, prolonged sitting, and bending forward, or with bending and lifting.1

Vertebrogenic Pain Has a Clear Diagnosis

To confirm that a patient has vertebrogenic pain, physicians use MRI to look for specific changes that occur with endplate inflammation, which are called Modic changes.

Endplates

Ablating the Basivertebral Nerve Is the Key

The basivertebral nerve enters through an opening in the back of the vertebral body and branches near the center of the vertebral body, sending nerves to innervate the superior and inferior endplates. These nerve endings transmit pain signals from the endplate to the brain and have been shown to increase in number with endplate damage or degeneration. 2-4

The Latest Living Proof

Boston Scientific Announces Positive Noridian Local Coverage Determination for the Intracept™ Procedure

Policy expands physician and patient access for vertebrogenic low back pain treatment.

Learn more

Relievant Medsystems Announces Positive Coverage Policy from Humana for the Intracept Procedure

The coverage went into effect on Thursday, November 2, 2023, and expands access to the procedure, when clinically appropriate, to more than 13 million patients.

Learn more

Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield

The coverage went into effect on Wednesday, September 27, 2023, and expands access to the procedure, when clinically appropriate, to more than 36 million patients.

Learn more

Proven Relief of Vertebrogenic Pain

NEARLY 80%

of patients in a recent long-term study would have the Intracept Procedure again for the same condition.

LESS THAN 0.2%

rate of serious device or procedure-related complications reported.

AFTER 5 YEARS, 65% OF

patients reported they had resumed the level of activity they enjoyed prior to low back pain in a recent long-term study.

BASED ON OVER 30 YEARS

of research.

Take the Next Step

Find a Doctor

In a few steps, see if you may benefit from the procedure, and connect with an Intracept-trained physician near you.

ZIP Code

Join the Intracept Physician Community

Add the Intracept Procedure to your practice, gaining the clinical support, peer expertise, and program development resources needed to bring Living Proof to your patients.

As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure. See important safety information below.

Physicians: See Indications, Contraindications, and Risks

The Intracept Procedure Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).

Use of the Intracept Procedure Intraosseous Nerve Ablation System is contraindicated in:

  • Patients with severe cardiac or pulmonary compromise
  • Patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal)
  • Patients with active systemic infection or local infection in the area to be treated
  • Patients who are pregnant
  • Skeletally immature patients (generally < 18 years of age)
  • Patients with active implantable pulse generators (e.g., pacemakers, defibrillators)
  • Situations where unintended tissue damage may result, based on the clinical assessment by the physician
  • Application with electrosurgical instruments NOT tested and specified for use with the Relievant RFG
Patients: See the Indications & Risks Involved
  • The Intracept Access Instruments and the Intracept RF Probe are single patient use only. The Introducer Cannula, Diamond Stylet, Bevel Stylet, J-Stylet, Straight Stylet, Drill, and Probe may be used to treat up to a maximum of four (4) vertebrae (L3, L4, L5, S1) on a single patient, while the Curved Cannula may only be used on one (1) vertebra on a single patient.
  • As with any surgical instrument, careful attention must be exercised to ensure that excessive force is not placed on the Instruments or Probe. Excessive force can result in product failure.
  • Prior to the procedure, CT or MRI imaging must be utilized to help define the desired treatment site and define working anatomical landmarks that can be used for mapping access to the treatment site.
  • The device should be manipulated only while under fluoroscopic or CT observation.
  • DO NOT use this device in the presence of flammable anesthetics, other flammable gases or objects, near flammable fluids such as skin prepping agents and tinctures, or oxidizing agents. Observe appropriate fire precautions at all times. There is a risk of pooling of flammable solutions under the patient or in body depressions and cavities.
  • Fluids pooled in the body depressions and cavities of the patient should be mopped up before RFG is used.
  • There is a danger of ignition of endogenous gases (e.g., cotton and gauze saturated with oxygen may be ignited by sparks produced during normal use of the RFG).
  • Operator may choose to use smoke-plume extraction apparatus, though the indicated procedure is unlikely to produce noticeable smoke
  • The Probe is for use WITHOUT a neutral electrode (ie., a grounding pad).
  • Discontinue use if inaccurate, erratic or sluggish temperature readings are observed. Use of damaged equipment may cause patient injury.
  • Prior to operation, visually inspect the Probe and RF for physical damage, obvious cracks in insulation or loose parts.
  • During power delivery, the cable should not come in direct contact with the patient's skin or other patient leads.
  • Safety and effectiveness in patients with conditions that are associated with poor bone quality such as osteoporosis have not been established.

CONTRAINDICATIONS

Use of the Intracept Intraosseous Nerve Ablation System is contraindicated in:

  • Patients with severe cardiac or pulmonary compromise
  • Patients with active implantable pulse generators (e.g. pacemakers, defibrillators)
  • Patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal)
  • Patients with active systemic infection or local infection in the area to be treated
  • Patients who are pregnant
  • Skeletally immature patients (generally ≤ 18 years of age)

WARNINGS

  • Do not use if package is opened or damaged as product integrity and/or sterility may be compromised.
  • Do not use after the expiration date has passed as product integrity and/or sterility may be compromised.
  • Do not re-sterilize or reuse. Re-sterilization or reuse may result in cross contamination, patient infection, or device malfunction.
  • Reconditioning, refurbishing, repair or modification of the device to enable further use is prohibited.
  • Do not use this product if you have not been properly trained in its use. Physicians using the device should be familiar with the physiology and pathology of the selected anatomy to be treated and be trained in the performance of the chosen surgical technique. Improper surgical use and technique may lead to suboptimal clinical outcomes.
  • Read and understand the Instructions For Use ("IFU*) completely prior to use.
  • The Intracept System must be used with the Relievant Medsystems RF Generator in order to provide the required treatment parameters.
  • Failure of the RFG could result in an unintended increase of output power to the Probe.
  • The Intracept RF Probe may interfere and adversely influence the operation of other electronic equipment.
  1. Koreckij T, Kreiner S, Khalil JG, Smuck M, Markman J, Garfin S. Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 24-month treatment arm results. NASSJ. Published online October 26, 2021. DOI: https://doi.org/10.1016/j.xnsj.2021.100089
  2. Fras C, Kravetz P, Mody DR, Heggeness MH. Substance P-containing nerves within the human vertebral body: an immunohistochemical study of the basivertebral nerve. The Spine Journal: Official Journal of the North American Spine Society. 2003;3(1):63-7.
  3. Bailey JF, Liebenberg E, Degmetich S, Lotz JC. Innervation patterns of PGP 9.5-positive nerve fibers within the human lumbar vertebra. Journal of Anatomy 2011;218(3):263-70.
  4. Lotz JC, Fields AJ, Liebenberg EC. The Role of the Vertebral End Plate in Low Back Pain. Global Spine J 2013;03:153-64.